A double-blind, randomized, placebo-controlled, multi-center, Clinical Trial of ofatumumab, a fully human monoclonal anti-CD20 antibody in patients with moderate to severe stage Chronic Obstructive Pulmonary Disease.
Phase of Trial: Phase II
Latest Information Update: 01 Nov 2012
At a glance
- Drugs Ofatumumab (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Genmab
- 01 Nov 2012 Planned number of patients changed from 40 to 60.
- 28 Aug 2011 New trial record